Aimmune Therapeutics, Inc. announced that it has enrolled the first patient in the pivotal Phase 3 PALISADE trial of its lead product candidate, AR101 for the treatment of peanut allergy. The company named Sue Barrowcliffe as General Manager of Europe and an executive officer of the company, effective January 2016. Ms. Barrowcliffe has been serving as its Senior Vice President, Regulatory, and Head of Europe.

In her new role, Ms. Barrowcliffe will oversee all European operations, including product development efforts and preparations for a potential commercial launch of AR101 in Europe. Appointed William Turner as Senior Vice President, Regulatory Affairs and Quality. Mr. Turner will have global responsibility for regulatory matters.

He brings 20 years of regulatory experience to the company, including senior positions at Dynavax and Medimmune.